A61K 2239/46
Indexing codes associated with cellular immunotherapy of group a61k40/00: characterised by the
Official title: characterised by the cancer treated
A61K2239/46 (Indexing codes associated with cellular immunotherapy of group a61k40/00: characterised by the) appears on 2,256 US grants and 5,463 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,256
- Published applications
- 5,463
- Assignees
- 1,578
- Inventors
- 8,187
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 4 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 17 | 0 |
| 1999 | 10 | 0 |
| 2000 | 12 | 0 |
| 2001 | 7 | 6 |
| 2002 | 24 | 46 |
| 2003 | 12 | 43 |
| 2004 | 12 | 43 |
| 2005 | 6 | 37 |
| 2006 | 16 | 48 |
| 2007 | 3 | 40 |
| 2008 | 19 | 49 |
| 2009 | 15 | 55 |
| 2010 | 25 | 55 |
| 2011 | 32 | 64 |
| 2012 | 30 | 68 |
| 2013 | 41 | 64 |
| 2014 | 38 | 92 |
| 2015 | 46 | 96 |
| 2016 | 63 | 129 |
| 2017 | 68 | 183 |
| 2018 | 83 | 228 |
| 2019 | 93 | 339 |
| 2020 | 178 | 459 |
| 2021 | 163 | 555 |
| 2022 | 187 | 635 |
| 2023 | 212 | 589 |
| 2024 | 255 | 658 |
| 2025 | 316 | 497 |
| 2026 | 256 | 385 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Chimeric antigen receptor t cells and methods of use thereof8 Oct 2026US 2026/0308521 A1Augusta University Research Institute, Inc.
- Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse8 Oct 2026US 2026/0308532 A1Fred Hutchinson Cancer Center
- Car-t cells co-expressing cd40l1 Oct 2026US 2026/0294969 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Chimeric cytokine receptors and methods of use thereof1 Oct 2026US 2026/0294970 A1Legend Biotech USA Inc.
Most cited
By later US patents
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy258US 8,034,334 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- CD19-specific chimeric T cell receptor231US 7,446,179 B2City of Hope · 2008